Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of iptacopan in C3 glomerulopathy or idiopathic immune-complex membranoproliferative glomerulonephritis
NL-OMON56390Phase 3Recruiting
- Sponsor
- Novartis
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of Iptacopan in Complement 3 glomerulopathy (C3G) and Primary immune complex membranoproliferative glomerulonephritis (MPGN) (2 arms), sponsored by Novartis. Primary endpoints: Composite renal endpoint at 9 months in native C3 glomerulopathy cohort and Long-term safety and tolerability. Started May 2023; status: recruiting.
02
Drugs
Iptacopan
03
Conditions
Complement 3 glomerulopathy (C3G)Primary immune complex membranoproliferative glomerulonephritis (MPGN)
Beyond the preview
Go deeper on NL-OMON56390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56390.